215 related articles for article (PubMed ID: 30792536)
1. BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer.
Shimada Y; Muneoka Y; Nagahashi M; Ichikawa H; Tajima Y; Hirose Y; Ando T; Nakano M; Sakata J; Kameyama H; Takii Y; Ling Y; Okuda S; Takabe K; Wakai T
Sci Rep; 2019 Feb; 9(1):2466. PubMed ID: 30792536
[TBL] [Abstract][Full Text] [Related]
2. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions.
Shimada Y; Tajima Y; Nagahashi M; Ichikawa H; Oyanagi H; Okuda S; Takabe K; Wakai T
J Surg Res; 2018 Dec; 232():72-81. PubMed ID: 30463788
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis.
Gil-Raga M; Jantus-Lewintre E; Gallach S; Giner-Bosch V; Frangi-Caregnato A; Safont-Aguilera MJ; Garde-Noguera J; Zorraquino-Pina E; García-Martínez M; Camps-Herrero C
Clin Transl Oncol; 2018 Nov; 20(11):1422-1429. PubMed ID: 29802524
[TBL] [Abstract][Full Text] [Related]
5. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
[TBL] [Abstract][Full Text] [Related]
6. RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.
Matsumoto A; Shimada Y; Nakano M; Oyanagi H; Tajima Y; Nakano M; Kameyama H; Hirose Y; Ichikawa H; Nagahashi M; Nogami H; Maruyama S; Takii Y; Ling Y; Okuda S; Wakai T
Oncol Rep; 2020 Jun; 43(6):1853-1862. PubMed ID: 32236609
[TBL] [Abstract][Full Text] [Related]
7. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
8. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J
Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797
[TBL] [Abstract][Full Text] [Related]
9. Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.
Amaki-Takao M; Yamaguchi T; Natsume S; Iijima T; Wakaume R; Takahashi K; Matsumoto H; Miyaki M
Oncology; 2016; 91(3):162-70. PubMed ID: 27404270
[TBL] [Abstract][Full Text] [Related]
10. A validated prognostic classifier for
Loupakis F; Intini R; Cremolini C; Orlandi A; Sartore-Bianchi A; Pietrantonio F; Pella N; Spallanzani A; Dell'Aquila E; Scartozzi M; De Luca E; Rimassa L; Formica V; Leone F; Calvetti L; Aprile G; Antonuzzo L; Urbano F; Prenen H; Negri F; Di Donato S; Buonandi P; Tomasello G; Avallone A; Zustovich F; Moretto R; Antoniotti C; Salvatore L; Calegari MA; Siena S; Morano F; Ongaro E; Cascinu S; Santini D; Ziranu P; Schirripa M; Buggin F; Prete AA; Depetris I; Biason P; Lonardi S; Zagonel V; Fassan M; Di Maio M
Eur J Cancer; 2019 Sep; 118():121-130. PubMed ID: 31330487
[TBL] [Abstract][Full Text] [Related]
11.
Jones JC; Renfro LA; Al-Shamsi HO; Schrock AB; Rankin A; Zhang BY; Kasi PM; Voss JS; Leal AD; Sun J; Ross J; Ali SM; Hubbard JM; Kipp BR; McWilliams RR; Kopetz S; Wolff RA; Grothey A
J Clin Oncol; 2017 Aug; 35(23):2624-2630. PubMed ID: 28486044
[TBL] [Abstract][Full Text] [Related]
12. BRAF
Trivieri N; Pracella R; Cariglia MG; Panebianco C; Parrella P; Visioli A; Giani F; Soriano AA; Barile C; Canistro G; Latiano TP; Dimitri L; Bazzocchi F; Cassano D; Vescovi AL; Pazienza V; Binda E
J Exp Clin Cancer Res; 2020 Dec; 39(1):285. PubMed ID: 33317591
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
[TBL] [Abstract][Full Text] [Related]
14. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
[TBL] [Abstract][Full Text] [Related]
15. BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.
Roma C; Rachiglio AM; Pasquale R; Fenizia F; Iannaccone A; Tatangelo F; Antinolfi G; Parrella P; Graziano P; Sabatino L; Colantuoni V; Botti G; Maiello E; Normanno N
Cancer Biol Ther; 2016 Aug; 17(8):840-8. PubMed ID: 27261210
[TBL] [Abstract][Full Text] [Related]
16. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
[TBL] [Abstract][Full Text] [Related]
17. Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
Osumi H; Shinozaki E; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Takahari D; Ooki A; Suzuki T; Ota Y; Nakayama I; Chin K; Miki Y; Yamaguchi K
Int J Cancer; 2019 Nov; 145(9):2488-2495. PubMed ID: 30963570
[TBL] [Abstract][Full Text] [Related]
18. Metastatic pattern is a prognostic factor in BRAF
Ji J; Sandhu J; Wang C; Fakih M
Cancer Treat Res Commun; 2023; 35():100714. PubMed ID: 37126990
[TBL] [Abstract][Full Text] [Related]
19. Population-based Screening for
Chu JE; Johnson B; Kugathasan L; Morris VK; Raghav K; Swanson L; Lim HJ; Renouf DJ; Gill S; Wolber R; Karsan A; Kopetz S; Schaeffer DF; Loree JM
Clin Cancer Res; 2020 Sep; 26(17):4599-4605. PubMed ID: 32571791
[TBL] [Abstract][Full Text] [Related]
20. Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study.
Taniguchi H; Okamoto W; Muro K; Akagi K; Hara H; Nishina T; Kajiwara T; Denda T; Hironaka S; Kudo T; Satoh T; Yamanaka T; Abe Y; Fukushima Y; Yoshino T
Neoplasia; 2018 Dec; 20(12):1219-1226. PubMed ID: 30412858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
